NasdaqGS:IFRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. More Details


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has InflaRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IFRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IFRX's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-3.4%

IFRX

1.9%

US Biotechs

2.1%

US Market


1 Year Return

17.1%

IFRX

21.2%

US Biotechs

19.8%

US Market

Return vs Industry: IFRX underperformed the US Biotechs industry which returned 21.1% over the past year.

Return vs Market: IFRX underperformed the US Market which returned 19.7% over the past year.


Shareholder returns

IFRXIndustryMarket
7 Day-3.4%1.9%2.1%
30 Day3.6%6.5%8.1%
90 Day-8.9%7.1%6.0%
1 Year17.1%17.1%23.3%21.2%22.5%19.8%
3 Year-80.9%-80.9%21.7%15.4%46.5%36.8%
5 Yearn/a14.9%7.0%96.9%75.3%

Long-Term Price Volatility Vs. Market

How volatile is InflaRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InflaRx undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IFRX ($3.95) is trading below our estimate of fair value ($12.29)

Significantly Below Fair Value: IFRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IFRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IFRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IFRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IFRX is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (3.5x).


Next Steps

Future Growth

How is InflaRx forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

0.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IFRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IFRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IFRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IFRX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if IFRX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IFRX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has InflaRx performed over the past 5 years?

-34.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IFRX is currently unprofitable.

Growing Profit Margin: IFRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IFRX is unprofitable, and losses have increased over the past 5 years at a rate of 34.9% per year.

Accelerating Growth: Unable to compare IFRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IFRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: IFRX has a negative Return on Equity (-43.22%), as it is currently unprofitable.


Next Steps

Financial Health

How is InflaRx's financial position?


Financial Position Analysis

Short Term Liabilities: IFRX's short term assets (€99.2M) exceed its short term liabilities (€11.5M).

Long Term Liabilities: IFRX's short term assets (€99.2M) exceed its long term liabilities (€158.5K).


Debt to Equity History and Analysis

Debt Level: IFRX is debt free.

Reducing Debt: IFRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IFRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IFRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is InflaRx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IFRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IFRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IFRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IFRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IFRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average management tenure


CEO

Niels Riedemann (48 yo)

13.83yrs

Tenure

Prof. Dr. Niels C. Riedemann, M.D. is a Co-Founder of InflaRx GmbH and has been its Chief Executive Officer and Executive Director since 2007. Dr. Riedemann spent several years in basic science at the Univ...


Leadership Team

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founder13.83yrsno data3.79%
€ 4.2m
Renfeng Guo
Co-Founderno datano data6.18%
€ 6.9m
Thomas Taapken
Chief Financial Officer0.083yrno datano data
Jordan Silverstein
Head of Corporate Development & Strategyno datano datano data
Maria Habel
Head of Preclinical Research & Development7.83yrsno datano data
Katrin Reiher
Head of Quality Management7.83yrsno datano data
Jordan Zwick
Chief Strategy Officerno datano datano data
Korinna Pilz
Global Head of Clinical Research & Development0.83yrno datano data

7.8yrs

Average Tenure

48yo

Average Age

Experienced Management: IFRX's management team is seasoned and experienced (7.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Niels Riedemann
Co-Founder13.83yrsno data3.79%
€ 4.2m
Renfeng Guo
Co-Founderno datano data6.18%
€ 6.9m
Katrin Uschmann
Independent Non-Executive Deputy Chairwoman13.83yrsno datano data
Nicolas Fulpius
Independent Chairman of the Board13.83yrsno data1.82%
€ 2.0m
K. Reinhart
Member of Scientific Advisory Boardno datano datano data
P. Ward
Member of Scientific Advisory Boardno datano datano data
Richard Brudnick
Independent Non-Executive Director1.5yrsno data0.18%
€ 197.5k
Lina Ma
Independent Non-Executive Director4.17yrsno datano data
Mark Kubler
Independent Non-Executive Director5.83yrsno data3.4%
€ 3.8m

5.8yrs

Average Tenure

48yo

Average Age

Experienced Board: IFRX's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.1%.


Top Shareholders

Company Information

InflaRx N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InflaRx N.V.
  • Ticker: IFRX
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$111.502m
  • Shares outstanding: 28.23m
  • Website: https://www.inflarx.de

Number of Employees


Location

  • InflaRx N.V.
  • Winzerlaer Str. 2
  • Jena
  • Thuringia
  • 7745
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IFRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2017
IF0DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2017
IFRX NBMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2017
IF0XTRA (XETRA Trading Platform)YesCommon StockDEEURNov 2017

Biography

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is invo...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/28 00:26
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.